The maximum they will go up in salary is 180. They're going to struggle finding quality canadites for this launch. 175 needs to be the bottom. Your avg should be around 200.
Company car
Unlimited pto
50k IC
If they're set in those salaries, than they need to lower expectations and experience for those applying. This would be good for someone with 2 years or less in rare. Good luck
I can confirm the above parameters from my interview, and they should understand that the competitor is offering substantially more. Neither drug will sell itself, which is why experience matters.
Something tells me you don’t work here. The reason that there’s hardly any info on Cafepharma about apellis? Because 90% of people are happy here, which is rare. Great culture, great benefits. There’s challenges like at any company, but I’ve been impressed with how they’ve been handled.
Something tells me you don’t work here. The reason that there’s hardly any info on Cafepharma about apellis? Because 90% of people are happy here, which is rare. Great culture, great benefits. There’s challenges like at any company, but I’ve been impressed with how they’ve been handled.
The maximum they will go up in salary is 180. They're going to struggle finding quality canadites for this launch. 175 needs to be the bottom. Your avg should be around 200.
Company car
Unlimited pto
50k IC
If they're set in those salaries, than they need to lower expectations and experience for those applying. This would be good for someone with 2 years or less in rare. Good luck
I took one look at financials and that kept me from pursuing a role. The salary is weak for experienced reps, most will already be in that range and don't have much of an incentive to leave. The stock is down 57% in the last year so the options they are offering aren't enticing either.
I took one look at financials and that kept me from pursuing a role. The salary is weak for experienced reps, most will already be in that range and don't have much of an incentive to leave. The stock is down 57% in the last year so the options they are offering aren't enticing either.